Latest Articles
I regularly analyze current developments in pharma packaging,
regulatory affairs, and communication — here on my blog.
Roche: Tam-Peli Phase III Data
Mechanism of action of an antibody-drug conjugate (ADC): the antibody binds to a target protein on the surface of the tumor cell and, together with its attached drug payload, is taken up into the cell. Once released from the antibody, the payload exerts its cytotoxic...
TrumpRx and the Fertility Deal
What EMD Serono's Pricing Agreement Really Means An 84 percent discount on fertility medications, a new government-branded sales platform, and a pharmaceutical company voluntarily signing on to a program that carries the president's name: on the surface, the deal...
Sanofi’s Painful Reset
How a New CEO Is Burying Three Blockbuster Hopes A leadership change, three failed late-stage programs, and a ticking patent clock: how Sanofi is trying to reposition itself before its own blockbuster Dupixent comes into the crosshairs of biosimilar competition When a...
Wainua Follow-Up
What the ESC Congress Really Reveals About the Failure Six weeks after the initial shock, Munich delivers the answers — and they're more complicated than the July headlines suggested When AstraZeneca and Ionis Pharmaceuticals announced in July 2026 that their compound...
Roche Goes After the Obesity Drug
The $2.3 Billion License With Hanmi Pharm A South Korean compound, a new mechanism, a record deal — how Roche is strengthening its position in today's most fiercely contested pharma market While Eli Lilly and Novo Nordisk battle for dominance in oral GLP-1 tablets,...
The GLP-1 Race: Lilly vs. Novo Nordisk
The race for the oral GLP-1 tablet: Novo Nordisk and Eli Lilly are fighting for market share in a market projected to reach $130–200 billion by 2030. How Eli Lilly and Novo Nordisk Are Fighting Over the Biggest Pharma Market Today A market that went from a diabetes...
Geropharm vs. Novo Nordisk
Russia's Patent Dispute Over Semaglutide How a company that withdrew from a market became the target of its own patents A Russian pharmaceutical company is suing one of the industry's largest corporations — and asking a court to grant it the right to use five patents...
Wainua: What the Failed Heart Drug Reveals
What a Failed Heart Drug Reveals About an Entire Drug Class A study with 1,432 patients, an established mechanism of action, a billion-dollar market — and then a result nobody expected. When AstraZeneca and Ionis Pharmaceuticals announced in July 2026 that their...
Daraxonrasib: The Untouchable Protein
Mechanism of action of daraxonrasib: The compound first binds to the chaperone protein cyclophilin A. The resulting complex then binds to the active, GTP-bound form of RAS — RAS(ON). The resulting tri-complex sterically blocks signal transmission to downstream...
China’s Pharma Catch-Up
Record investment, shrinking share: What China's catch-up means for pharma R&D strategy At first glance, the figures in the latest VCI report seem contradictory. In 2025, Germany's chemical and pharmaceutical industry invested just under 16 billion euros in research...
Anti-IL-6 Antibody Therapy: From Filing to Finished Text
Mechanism of action of an anti-IL-6 antibody therapy: the antibody binds directly to the cytokine interleukin-6 (IL-6), preventing it from docking onto the IL-6 receptor. This blocks the pro-inflammatory signal and reduces the inflammatory response. Schematic, not to...
Phone
Adresse
Römerweg 34,
79199 Kirchzarten, Deutschland